EUVIMEDEUVIMED entdecken
Crossref

Fidaxomicin: novel antibiotic for Clostridium difficile infection

Steve Chaplin, Mark Wilcox

Prescriber · 2013

DOI: 10.1002/psb.1002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Prescriber, 2013. Verfasst von Steve Chaplin und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fidaxomicin (Dificlir) is a new antibiotic licensed for the treatment of C. difficile infection in adults. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Professor Mark Wilcox discusses its place in treatment.

Zitieren

APA

Chaplin, S., & Wilcox, M. (2013). Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. https://doi.org/10.1002/psb.1002

Vancouver

Chaplin S, Wilcox M. Fidaxomicin: novel antibiotic for Clostridium difficile infection. Prescriber. 2013. doi:10.1002/psb.1002

BibTeX
@article{Chaplin2013,
  author = {Chaplin, Steve and Wilcox, Mark},
  title = {Fidaxomicin: novel antibiotic for Clostridium difficile infection},
  journal = {Prescriber},
  year = {2013},
  doi = {10.1002/psb.1002}
}
Kostenlos starten →